Ashish Gautam

1.1k total citations
26 papers, 899 citations indexed

About

Ashish Gautam is a scholar working on Pathology and Forensic Medicine, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Ashish Gautam has authored 26 papers receiving a total of 899 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Pathology and Forensic Medicine, 15 papers in Oncology and 9 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Ashish Gautam's work include Lymphoma Diagnosis and Treatment (15 papers), Lung Cancer Treatments and Mutations (9 papers) and Viral-associated cancers and disorders (6 papers). Ashish Gautam is often cited by papers focused on Lymphoma Diagnosis and Treatment (15 papers), Lung Cancer Treatments and Mutations (9 papers) and Viral-associated cancers and disorders (6 papers). Ashish Gautam collaborates with scholars based in United States, United Kingdom and France. Ashish Gautam's co-authors include Gerold Bepler, Alan Cantor, Anupama Sharma, George R. Simon, Swati Sharma, Irina Kusmartseva, Eric Sommers, Eric B. Haura, Lary A. Robinson and John Radford and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Ashish Gautam

23 papers receiving 881 citations

Peers

Countries citing papers authored by Ashish Gautam

Since Specialization

Citations

This map shows the geographic impact of Ashish Gautam's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ashish Gautam with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ashish Gautam more than expected).

Fields of papers citing papers by Ashish Gautam

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ashish Gautam. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ashish Gautam. The network helps show where Ashish Gautam may publish in the future.

Co-authorship network of co-authors of Ashish Gautam

This figure shows the co-authorship network connecting the top 25 collaborators of Ashish Gautam. A scholar is included among the top collaborators of Ashish Gautam based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ashish Gautam. Ashish Gautam is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Rationale and design for a phase IIIb trial of first-line tremelimumab plus durvalumab versus pembrolizumab, in combination with chemotherapy, in patients with non-squamous metastatic non-small-cell lung cancer and mutations or co-mutations in STK11, KEAP1 , or KRAS : the TRITON study 2025 ·Therapeutic Advances in Medical Oncology ·Ferdinandos Skoulidis, (unknown), (unknown), Ticiana Leal, (unknown), Stephen V. Liu, Eric Nadler, Sandip Pravin Patel, Solange Peters, (unknown), Ashish Gautam, (unknown), (unknown), John V. Heymach	0
2	P4.11D.01 TRITON: Tremelimumab + Durvalumab + Chemotherapy (CT) vs Pembrolizumab + CT in mNSCLC with STK11, KEAP1 and/or KRAS Mutations 2024 ·Journal of Thoracic Oncology ·(unknown), (unknown), (unknown), Ticiana Leal, (unknown), (unknown), Eric Nadler, Sandip Pravin Patel, (unknown), Vamsidhar Velcheti, Ashish Gautam, Ugochi Emeribe, (unknown), John V. Heymach	0
3	TRITON: Phase 3b study of tremelimumab (T) + durvalumab (D) vs pembrolizumab (P), in combination with chemotherapy (CT), in non-squamous (NSQ) metastatic NSCLC (mNSCLC) with STK11and/or KEAP1 and/or KRAS mutations. 2024 ·Journal of Clinical Oncology ·Ferdinandos Skoulidis, Hossein Borghaei, Edward B. Garon, Ticiana Leal, Stephen V. Liu, Eric Nadler, Sandip Pravin Patel, Vamsidhar Velcheti, Ashish Gautam, (unknown), (unknown), John V. Heymach	4
4	Older patients (aged ≥60 years) with previously untreated advanced-stage classical Hodgkin lymphoma: a detailed analysis from the phase III ECHELON-1 study 2021 ·Haematologica ·Andrew M. Evens, Joseph M. Connors, Anas Younes, Stephen M. Ansell, Won Seog Kim, John Radford, Tatyana Feldman, Joseph M. Tuscano, Kerry J. Savage, Yasuhiro Oki, Andrew Grigg, Christopher Pocock, Monika Długosz‐Danecka, Keenan Fenton, Andres Forero‐Torres, Rachael Liu, Hina Jolin, Ashish Gautam, Andrea Gallamini	31
5	Brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine in patients with advanced‐stage, classical Hodgkin lymphoma: A prespecified subgroup analysis of high‐risk patients from the ECHELON‐1 study 2021 ·Hematological Oncology ·Martin Hutchings, John Radford, Stephen M. Ansell, Árpád Illés, Anna Sureda, Joseph M. Connors, (unknown), Hirohiko Shibayama, Jeremy S. Abramson, Neil Chua, Jonathan W. Friedberg, (unknown), Ann S. LaCasce, Lysiane Molina, (unknown), Keenan Fenton, Hina Jolin, Rachael Liu, Ashish Gautam, Andrea Gallamini	13
6	Primary prophylaxis with G-CSF may improve outcomes in patients with newly diagnosed stage III/IV Hodgkin lymphoma treated with brentuximab vedotin plus chemotherapy 2020 ·Leukemia & lymphoma ·David J. Straus, Graham P. Collins, Jan Walewski, Pier Luigi Zinzani, Andrew Grigg, Anna Sureda, Árpád Illés, Tae Min Kim, Sergey Alekseev, Lena Specht, Valéria Buccheri, Anas Younes, Joseph M. Connors, Andres Forero‐Torres, Keenan Fenton, Ashish Gautam, (unknown), Rachael Liu, Andrea Gallamini	10
7	EXPLORATORY BIOMARKER ANALYSIS IN THE PH 3 ECHELON‐1 STUDY: WORSE OUTCOME WITH ABVD IN PATIENTS WITH ELEVATED BASELINE LEVELS OF SCD30 AND TARC 2019 ·Hematological Oncology ·John Radford, Joseph M. Connors, Anas Younes, Andrea Gallamini, Stephen M. Ansell, (unknown), June‐Won Cheong, Ian W. Flinn, Nagesh Kalakonda, Mark Kaminski, Ruth Pettengell, Matthew Onsum, Neil C. Josephson, Shingo Kuroda, (unknown), Harry Miao, Ashish Gautam, William L. Trepicchio, Anna Sureda	0
8	Neutropenia during frontline treatment of advanced Hodgkin lymphoma: Incidence, risk factors, and management 2019 ·Critical Reviews in Oncology/Hematology ·Anna Sureda, Eva Domingo‐Doménech, Ashish Gautam	10
9	Response to brentuximab vedotin by CD30 expression: Results from five trials in PTCL, CTCL, and B-cell lymphomas. 2019 ·Journal of Clinical Oncology ·Deepa Jagadeesh, Sarah McCue Horwitz, Nancy L. Bartlett, Ranjana H. Advani, Eric D. Jacobsen, Madeleine Duvic, Ashish Gautam, Shangbang Rao, Matthew Onsum, Michelle A. Fanale, Youn H. Kim	7
10	Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin lymphoma (HL): Impact of cycle 2 PET result on modified progression-free survival (mPFS). 2018 ·Journal of Clinical Oncology ·Robert W. Chen, Stephen M. Ansell, Andrea Gallamini, Joseph M. Connors, Kerry J. Savage, Graham P. Collins, Andrew Grigg, Anna M. Sureda, Nilanjan Ghosh, Tatyana Feldman, Alexander Fosså, Evren Özdemir, Fritz Offner, (unknown), Keenan Fenton, Shih-Yuan Lee, Hina Jolin, Ashish Gautam, Martin Hutchings	6
11	Improving outcomes with brentuximab vedotin (BV) plus chemotherapy in patients with newly diagnosed advanced stage Hodgkin lymphoma. 2018 ·Journal of Clinical Oncology ·David J. Straus, Graham P. Collins, Jan Walewski, Pier Luigi Zinzani, Andrew Grigg, Anna M. Sureda, Árpád Illés, Tae Min Kim, (unknown), Lena Specht, Valéria Buccheri, Anas Younes, Joseph M. Connors, Ashish Gautam, (unknown), Keenan Fenton, (unknown), Andrea Gallamini	6
12	Older Patients (pts) with Previously Untreated Classical Hodgkin Lymphoma (cHL): A Detailed Analysis from the Phase 3 ECHELON-1 Study 2018 ·Blood ·Andrew M. Evens, Joseph M. Connors, Anas Younes, Stephen M. Ansell, Won Seog Kim, John Radford, Tatyana Feldman, Joseph M. Tuscano, Kerry J. Savage, Yasuhiro Oki, Andrew Grigg, Christopher Pocock, Monika Długosz‐Danecka, Keenan Fenton, (unknown), Rachael Liu, Harry Miao, Hina Jolin, Ashish Gautam, Andrea Gallamini	9
13	Brentuximab vedotin consolidation post-autologous stem cell transplant in Hodgkin lymphoma patients at risk of residual disease: number needed to treat 2017 ·Leukemia & lymphoma ·Ashish Gautam, Yanyan Zhu, Esprit Ma, Shih-Yuan Lee, Erin Zagadailov, (unknown), Akshara Richhariya, Vijayveer Bonthapally, Dirk Huebner	2
14	Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma: An updated review of published data from the named patient program 2016 ·Critical Reviews in Oncology/Hematology ·Pier Luigi Zinzani, Stephanie Sasse, John Radford, Ashish Gautam, Vijayveer Bonthapally	18
15	Brentuximab vedotin compared with other therapies in relapsed/refractory Hodgkin lymphoma post autologous stem cell transplant: median overall survival meta-analysis 2015 ·Current Medical Research and Opinion ·Vijayveer Bonthapally, Hongbo Yang, Rajeev Ayyagari, (unknown), (unknown), Eric Q. Wu, Ashish Gautam, Andy Chi, Dirk Huebner	9
16	Suppression of Lung Tumor Formation by the Regulatory Subunit of Ribonucleotide Reductase 2006 ·Cancer Research ·Ashish Gautam, Gerold Bepler	68
17	RRM1 and PTEN As Prognostic Parameters for Overall and Disease-Free Survival in Patients With Non–Small-Cell Lung Cancer 2004 ·Journal of Clinical Oncology ·Gerold Bepler, Swati Sharma, Alan Cantor, Ashish Gautam, Eric B. Haura, George R. Simon, Anupama Sharma, Eric Sommers, Lary A. Robinson	154
18	Ribonucleotide reductase M1 gene promoter activity, polymorphisms, population frequencies, and clinical relevance 2004 ·Lung Cancer ·Gerold Bepler, Zhong Zheng, Ashish Gautam, Swati Sharma, Alan Cantor, Anupama Sharma, W. Douglas Cress, Young‐Chul Kim, Rafael Rosell, Colleen M. McBride, Lary A. Robinson, Eric Sommers, Eric B. Haura	68
19	RRM1-induced metastasis suppression through PTEN-regulated pathways 2003 ·Oncogene ·Ashish Gautam, (unknown), Gerold Bepler	127
20	Prognostic Significance of Molecular Genetic Aberrations on Chromosome Segment 11p15.5 in Non–Small-Cell Lung Cancer 2002 ·Journal of Clinical Oncology ·Gerold Bepler, Ashish Gautam, Lauren M. McIntyre, Amy Beck, David S. Chervinsky, Youngchul Kim, Diana M. Pitterle, Andrew Hyland	29

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact